Comparing Amvuttra vs Patisiran
| Amvuttra (vutrisiran) | Patisiran |
|
|---|
| Amvuttra (vutrisiran) | Patisiran |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Hereditary Amyloidosis, Cardiomyopathy of Transthyretin-Mediated Amyloidosis, Transthyretin-Related Amyloidosis. Amvuttra may also be used for purposes not listed in this medication guide. View more |
Prescription only
Prescribed for Hereditary Amyloidosis, Transthyretin-Related Amyloidosis. Patisiran may also be used for purposes not listed in this medication guide. |
Related suggestions Hereditary Amyloidosis
|
|||||||
| More about Amvuttra (vutrisiran) | More about Patisiran | ||||||||
| Ratings & Reviews | |||||||||
|
Amvuttra has an average rating of 5.0 out of 10 from a total of 1 ratings on Drugs.com. 0% of reviewers reported a positive effect, while 0% reported a negative effect. |
Be the first to share your experience with this drug. |
||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||
|
View all Amvuttra side effects |
View all Patisiran side effects |
||||||||
| Drug Class | |||||||||
| Generic Availability | |||||||||
|
N/A |
|||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||
View all Amvuttra prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||
| Dosage Forms | |||||||||
|
N/A |
||||||||
| Brand Names | |||||||||
|
N/A |
Onpattro | ||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||
|
5.2 hours |
76.8 hours |
||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | |||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||
| Drug Interactions | |||||||||
|
No known drug interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known drug interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||
| Disease Interactions | |||||||||
| First Approval Date | |||||||||
|
June 13, 2022 |
August 10, 2018 |
||||||||
| WADA Class View classifications | |||||||||
|
N/A |
N/A |
||||||||
| More Information | |||||||||
| Patient Resources | |||||||||
| Professional Resources | |||||||||
| Related Treatment Guide | |||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.